Publications scientifiques

Depuis le 27/02/2023
  1. Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice.
    de Germay S, Conte C, Micallef J, Bouquet E, Chouchana L, Lafaurie M, Pariente A; Pharmacoepidemiological group of the French Society of Pharmacology and Therapeutics (SFPT).
    Therapie. 2023
  2. [Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice]
    de Germay S, Conte C, Micallef J, Bouquet E, Chouchana L, Lafaurie M, Pariente A; au nom du groupe de pharmaco-épidémiologie de la Société Française de Pharmacologie et de Thérapeutique (SFPT).
    Therapie. 2023
  3. Drugs and the elderly: A complex interaction.
    Bégaud B, de Germay S, Noize P.
    Therapie. 2023
  4. [Analyze and use the results of clinical studies in the perspective of good use. Critical analysis, clinical research and levels of evidence]
    Pariente A, de Germay S.
    Rev Prat. 2023
  5. Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany.
    Hyeraci G, Gini R, Bezin J, Iannone LF, Benemei S, Lupi C, De Cesaris F, Geppetti P, Roberto G.
    Headache. 2023
  6. Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
    Benaboud S, Solas C, Bouchet S, Gregoire M, Lemaitre F, Venisse N, Lê MP, Muret P, Parant F, Neant N, Boujafaar S, Lagoutte-Renosi J, Garraffo R, Peytavin G.
    J Antimicrob Chemother. 2023
  7. Trends in use of benzodiazepines and Z-drugs in France from 2012 to 2020.
    Bénard-Laribière A, Pambrun E, Diop PY, Pariente A.
    Therapie. 2022
  8. Quelle place pour l’automatisation intelligente et l’intelligence artificielle pour préserver et renforcer l’expertise en vigilance devant l’augmentation des déclarations ?
    Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F.
    Therapie. 2022
  9. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
    Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F.
    Therapie. 2022
  10. Systematic review on sex differences for drug use after stroke.
    Perrier J, Renard M, Pariente A, Bezin J.
    Therapie. 2022
  11. Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
    Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, Montastruc F.
    Psychopharmacology (Berl). 2022
  12. Bidisciplinary dermatology-pharmacovigilance consultations: Results of a two-year study.
    Sanchez-Pena P, Milpied B, Darrigade AS, Miremont-Salamé G, Pariente A, Beylot Barry M.
    Ann Dermatol Venereol. 2022
  13. Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis.
    Spini A, Ciccone V, Rosellini P, Ziche M, Lucenteforte E, Salvo F, Donnini S.
    Cancers (Basel). 2022
  14. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
    Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, Pariente A, Faillie JL.
    Diabetes Care. 2022
  15. Transparency and robustness of safety signals.
    Khouri C, Fusaroli M, Salvo F, Raschi E.
    BMJ. 2022
  16. Incidence of Heart Failure following Exposure to a Protein Kinase Inhibitor (PKI), a French Population-based Study.
    Zelmat Y, Conte C, Noize P, Vabre C, Pajiep M, Lafaurie M, Lapeyre-Mestre M, Despas F.
    Br J Clin Pharmacol. 2022
  17. JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study.
    Gouverneur A, Avouac J, Prati C, Cracowski JL, Schaeverbeke T, Pariente A, Truchetet ME.
    Eur J Clin Pharmacol. 2022
  18. Second-degree burn induced by high-concentration topical capsaicin with mobility sequelae: a case report.
    Trin K, Perino J, Allouchery M, Géniaux H, Miremont G, Salvo F.
    Pain Pract. 2022
  19. Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
    Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F; French CML Group (FiLMC).
    Br J Haematol. 2022
  20. Adverse drug reaction related to drug shortage: A retrospective study on the French National Pharmacovigilance Database.
    Bourneau-Martin D, Babin M, Grandvuillemin A, Mullet C, Salvo F, Singier A, Cellier M, Fresse A, de Canecaude C, Pietri T, Drablier G, Geniaux H, Lagarce L, Laroche ML, Briet M; French Network of Regional Pharmacovigilance Centres.
    Br J Clin Pharmacol. 2023